| Primary |
| Metastases To Bone |
23.4% |
| Osteoporosis |
19.7% |
| Multiple Myeloma |
13.1% |
| Breast Cancer |
12.8% |
| Osteoporosis Postmenopausal |
6.4% |
| Prostate Cancer |
5.1% |
| Osteoporotic Fracture |
3.4% |
| Hypertension |
3.1% |
| Breast Cancer Metastatic |
2.3% |
| Analgesic Therapy |
1.3% |
| Bone Sarcoma |
1.3% |
| Pain |
1.3% |
| Prophylaxis |
1.2% |
| Osteolysis |
1.1% |
| Osteitis Deformans |
1.0% |
| Prostate Cancer Metastatic |
0.9% |
| Lung Neoplasm Malignant |
0.7% |
| Renal Cell Carcinoma |
0.7% |
| Bone Lesion |
0.6% |
| Osteopenia |
0.6% |
|
| Osteonecrosis |
21.8% |
| Tooth Extraction |
16.5% |
| Osteonecrosis Of Jaw |
14.7% |
| Death |
8.2% |
| Pain |
4.2% |
| Surgery |
4.1% |
| Bone Disorder |
3.6% |
| Pyrexia |
3.6% |
| Vomiting |
3.3% |
| Wound Closure |
3.1% |
| Toothache |
2.8% |
| Pain In Jaw |
2.8% |
| Wound Dehiscence |
2.5% |
| Tooth Loss |
1.5% |
| Renal Impairment |
1.3% |
| Swelling |
1.3% |
| Fall |
1.2% |
| Pain In Extremity |
1.2% |
| Pneumonia |
1.2% |
| Wound Debridement |
1.1% |
|
| Secondary |
| Breast Cancer |
16.3% |
| Multiple Myeloma |
13.0% |
| Osteoporosis |
11.9% |
| Metastases To Bone |
9.7% |
| Product Used For Unknown Indication |
9.0% |
| Drug Use For Unknown Indication |
6.8% |
| Prostate Cancer |
6.7% |
| Breast Cancer Metastatic |
4.3% |
| Osteoporotic Fracture |
3.8% |
| Hypertension |
3.3% |
| Osteolysis |
2.2% |
| Prophylaxis |
2.0% |
| Pain |
1.8% |
| Non-small Cell Lung Cancer Stage Iv |
1.8% |
| Metastatic Renal Cell Carcinoma |
1.7% |
| Prostate Cancer Metastatic |
1.3% |
| Non-small Cell Lung Cancer |
1.2% |
| Plasma Cell Myeloma |
1.1% |
| Osteoporosis Postmenopausal |
1.1% |
| Hypercalcaemia |
1.0% |
|
| Osteonecrosis |
25.8% |
| Osteonecrosis Of Jaw |
20.0% |
| Tooth Extraction |
7.0% |
| Vomiting |
5.1% |
| Femur Fracture |
4.9% |
| Pain |
4.3% |
| Renal Failure Acute |
4.3% |
| Pain In Jaw |
3.7% |
| Surgery |
3.1% |
| Urinary Tract Infection |
2.9% |
| Weight Decreased |
2.9% |
| Death |
2.5% |
| Renal Impairment |
2.5% |
| Pyrexia |
2.0% |
| Osteomyelitis |
1.8% |
| Toothache |
1.6% |
| Upper Limb Fracture |
1.6% |
| Neoplasm Malignant |
1.4% |
| Respiratory Failure |
1.4% |
| Pain In Extremity |
1.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
14.3% |
| Drug Use For Unknown Indication |
12.3% |
| Multiple Myeloma |
11.5% |
| Prostate Cancer |
9.8% |
| Prophylaxis |
5.8% |
| Pain |
5.5% |
| Hypertension |
4.8% |
| Metastases To Bone |
4.0% |
| Breast Cancer |
3.7% |
| Prostate Cancer Metastatic |
3.6% |
| Cancer Pain |
3.3% |
| Breast Cancer Metastatic |
3.3% |
| Nausea |
2.9% |
| Plasma Cell Myeloma |
2.9% |
| Constipation |
2.7% |
| Osteoporosis |
2.2% |
| Medical Diet |
1.9% |
| Insomnia |
1.8% |
| Premedication |
1.8% |
| Prostate Cancer Stage Iv |
1.8% |
|
| Thrombocytopenia |
9.5% |
| Vomiting |
8.2% |
| Sepsis |
7.1% |
| Pyrexia |
6.5% |
| Pneumonia |
6.0% |
| Urinary Tract Infection |
5.7% |
| Prostate Cancer |
5.4% |
| Renal Failure Acute |
5.2% |
| Drug Ineffective |
4.9% |
| Pleural Effusion |
4.6% |
| Weight Decreased |
4.6% |
| Anaemia |
4.4% |
| Death |
4.4% |
| Renal Failure |
4.4% |
| Osteonecrosis |
3.5% |
| Respiratory Failure |
3.3% |
| White Blood Cell Count Increased |
3.3% |
| Multiple Myeloma |
3.0% |
| Nausea |
3.0% |
| Pulmonary Embolism |
3.0% |
|
| Interacting |
| Breast Cancer |
53.5% |
| Product Used For Unknown Indication |
14.7% |
| Metastasis |
8.1% |
| Drug Use For Unknown Indication |
7.4% |
| Breast Cancer Metastatic |
5.0% |
| Crohn's Disease |
2.3% |
| Metastases To Bone |
1.6% |
| Plasma Cell Myeloma |
1.6% |
| Hypertension |
1.2% |
| Osteoporosis |
1.2% |
| Osteoporotic Fracture |
1.2% |
| Metastatic Renal Cell Carcinoma |
0.8% |
| Rheumatoid Arthritis |
0.8% |
| Metastases To Pleura |
0.4% |
| Pain |
0.4% |
|
| Weight Decreased |
38.2% |
| Osteonecrosis |
26.5% |
| Mobility Decreased |
8.8% |
| Cardio-respiratory Arrest |
5.9% |
| Thrombocytopenia |
5.9% |
| Gingival Recession |
2.9% |
| Haemophilus Bacteraemia |
2.9% |
| Leukopenia |
2.9% |
| Osteonecrosis Of Jaw |
2.9% |
| Septic Shock |
2.9% |
|
